U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

SRX2897200: GSM2654038: T5_JG5B-1_ERChIP_IDX10-ChIP-seq; Homo sapiens; ChIP-Seq
1 ILLUMINA (NextSeq 500) run: 34.4M spots, 5.2G bases, 1.9Gb downloads

Submitted by: NCBI (GEO)
Study: Estrogen signaling is reprogrammed in breast tumorigenesis
show Abstracthide Abstract
Limited knowledge of the changes in estrogen receptor (ER) signaling during the transformation of the normal mammary gland to breast cancer hinders the development of effective prevention and treatment strategies. Differences in estrogen signaling between normal human primary breast epithelial cells and primary breast tumors obtained immediately following surgical excision were explored. Transcriptional profiling of normal ER+ mature luminal mammary epithelial cells and ER+ breast tumors revealed significant difference in the response to estrogen stimulation. Consistent with these differences in gene expression, the normal and tumor ER cistromes were distinct and sufficient to segregate normal breast tissues from breast tumors. The selective enrichment of the DNA binding motif GRHL2 in the breast cancer-specific ER cistrome suggests that it may play a role in the differential function of ER in breast cancer. Depletion of GRHL2 resulted in altered ER binding and differential transcriptional responses to estrogen stimulation. Furthermore, GRHL2 was demonstrated to be essential for estrogen-stimulated proliferation of ER+ breast cancer cells. DLC1 was also identified as an estrogen-induced tumor suppressor in the normal mammary gland with decreased expression in breast cancer. In clinical cohorts, loss of DLC1 and gain of GRHL2 expression are associated with breast cancer and are independently predictive for worse survival. This study suggests that normal ER signaling is lost and tumor-specific ER signaling is gained during breast tumorigenesis. Unraveling these changes in ER signaling during breast cancer progression should aid the development of more effective prevention strategies and targeted therapeutics. SIGNIFICANCE STATEMENT: Abnormal estrogen receptor (ER) signaling drives the majority of breast cancers and is targeted by endocrine therapies. However, in normal breast tissue, ER signaling has been demonstrated to promote benign functions such as development and differentiation. Using genomic techniques to characterize ER function in normal breast and breast tumors, this study reveals differential patterns of ER signaling, suggesting that normal ER signaling is lost and tumorigenic ER signaling gained during breast tumor formation. Better understanding of this process can aid the development of improved breast cancer prevention strategies and therapies. Overall design: Methods: To model the normal breast epithelium, viable tissue specimens from patients undergoing reduction mammoplasty were obtained and enriched for breast epithelial cells via FACS. Fresh-frozen ER+ breast tumor samples were then obtained for comparison. RNA-seq, ChIP-seq for ER, and genome-wide CRISPR screening in the presence of estrogen stimulation were performed. These various modalities of genomic data were then integrated and analyzed to identify mechanistic patterns in breast tumorigenesis.
Sample: T5_JG5B-1_ERChIP_IDX10-ChIP-seq
SAMN07207026 • SRS2264646 • All experiments • All runs
Organism: Homo sapiens
Library:
Instrument: NextSeq 500
Strategy: ChIP-Seq
Source: GENOMIC
Selection: ChIP
Layout: PAIRED
Construction protocol: The tissue was collected fresh and sterile from the operating room and transported on ice to the pathologist in the absence of formalin fixative. Following pathological examination, tissue in excess of diagnostic requirements was collected and subsequently de-identified at the tissue bank. The tissue was then transported on ice to the laboratory. Samples that were collected in the evening were stored in media at 4C overnight. The duration from surgery to the commencement of tissue dissociation did not exceed 24 hrs, the majority of the samples were processed on the same day as surgery. Fragments of normal ER+ breast tissue were of insufficient cell number to utilize FACS after they were dissociated as described above, so epithelial cell enrichment was performed by utilizing magnetic EasySEP EpCAM beads (StemCell Technologies). Once the cells were washed in cold PBS, the appropriate amount of selection media and magnetic particles was added and incubated on ice for 15 minutes. Next, the tube was placed on the magnet at room temperature for five minutes and eluted with chilled media and this process was repeated for a total of four times to enrich for the ER+/EpCAM+ epithelial tumor cells. Immuno-labelling of normal cells was performed at 4C using PBS as a buffer and wash solution. Incubating the cell pellet with 0.1 mg/ml DNase, 1 mg/ml rat immunoglobulin and a 1/10 dilution of anti-CD16/CD32 receptor antibody for 10 min. was sufficient to block non-specific antibody binding. The cell suspension was then made up to a final concentration of 106 cells /40 l with dilution buffer. For primary human breast tissue, antibodies directed against human lineage markers CD31 (endothelial cells), CD45 (leukocytes) and CD235a (red blood cells) were used to prepare a Lin- cell population, and these PE-linked antibodies were negatively selected against. Primary antibodies were added at optimized dilutions and incubated for 25 min at 4C. The suspension was then washed, filtered using 40uM tube cap filters (Falcon) and centrifuged. Cells were resuspended in 0.5 g/ml propidium iodide (Sigma) before cell analysis and sorting to allow for only the selection of viable cells. Cell analysis and sorting was performed on either a FACS DIVA or FACS Aria (BD Biosciences) using a sheath pressure of 30 psi and nozzle size of 70 um. Cells were sorted into polystyrene FACS tubes (Westnet #352063) and collected into a mixture of 50% primary MEC media and 50% CDT. Reanalysis of the sorted populations routinely revealed a purity of more than 95%.
Experiment attributes:
GEO Accession: GSM2654038
Links:
Runs: 1 run, 34.4M spots, 5.2G bases, 1.9Gb
Run# of Spots# of BasesSizePublished
SRR566159034,429,5755.2G1.9Gb2018-06-05

ID:
4147992

Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...